Please use this identifier to cite or link to this item:
Title: No differences of immune activation and microbial translocation among HIV-infected children receiving combined antiretroviral therapy or protease inhibitor monotherapy.
Author: Falcon Neyra, Lola
Benmarzouk-Hidalgo, Omar J.
Madrid, Lola
Noguera Julian, Antoni
Fortuny Guasch, Claudia
Neth, Olaf
López Cortés, Luis F.
Keywords: Infants
Infeccions per VIH
Inhibidors enzimàtics
HIV infections
Antiretroviral agents
Enzyme inhibitors
Issue Date: Mar-2015
Publisher: Lippincott, Williams & Wilkins. Wolters Kluwer Health
Abstract: This is a cross-sectional study of 15 aviremic chronic HIV-infected children revealing no differences in immune activation (IA; HLA-DRCD38 CD4 and CD8 T cells, and sCD14) and microbial translocation (MT; lipopolysaccharides (LPS) and 16S rDNA) among HIV-infected patients under combined antiretroviral treatment (cART; n = 10) or ritonavir-boosted protease inhibitor monotherapy (mtPI/rtv; n = 5). In both cases, IA and MT were lower in healthy control children (n = 32). This observational study suggests that ritonavir boosted protease inhibitor monotherapy (mtPI/rtv) is not associated with an increased state of IA or MT as compared with children receiving cART.
Note: Reproducció del document publicat a:
It is part of: Medicine, 2015, vol. 94, num. 11, p. e521
Related resource:
ISSN: 0025-7974
Appears in Collections:Articles publicats en revistes (Cirurgia i Especialitats Medicoquirúrgiques)
Articles publicats en revistes (ISGlobal)

Files in This Item:
File Description SizeFormat 
660358.pdf150.54 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons